Current treatment options: Impact of cytogenetics on the course of myelodysplasia

Current Treatment Options in Oncology

Volumn 8, Issue 2, 2007, Pages 117-128

  Galili, Naomi ^a   Cerny, Jan ^a   Raza, Azra ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AZACITIDINE; CD1 ANTIGEN; CYCLOSPORIN; CYTOTOXIC AGENT; GYRASE INHIBITOR; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LENALIDOMIDE; MYC PROTEIN; PROTEIN TYROSINE KINASE; SURVIVIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RISK; CELL INTERACTION; CHROMOSOME 20; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; GENE DELETION; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; MACROCYTIC ANEMIA; MEGAKARYOPOIESIS; MOLECULAR CLONING; MONOSOMY 7; MYELODYSPLASIA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; SEX RATIO; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TRISOMY 8; GENETICS; MYELODYSPLASTIC SYNDROME; REVIEW;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 38149017735     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0017-1     Document Type: Article

References (54)

1. Bennett JM, Catovsky D, Daniel MT, et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189-199
2. Harris NL, Jaffe ES, Diebold J, et al. (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10(12):1419-1432
3. Yunis JJ, Lobell M, Arnesen MA, Oken MM, et al (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 68:189-194
4. Morel P, Hebbar M, Lai J-L, A, et al (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323
5. Parlier V, Van Melle G, Berise P, PM, et al (1995) Prediction of 18-month survival in patients with primary myelodysplastic syndrome: A regression model and a scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogenet 81:158-165
6. Jotterand M, Parlier V (1996) Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma 23:253-266
7. Greenberg P, Cox C, LeBeau MM, Fenaux P, et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
8. Vallespi T, Imbert M, Mecucci C, Preudhomme C, et al (1998) Diagnosis, classification and cytogenetics of myelodysplastic syndromes. Haematologica 83:258-275
9. Morel P, Hebbar M, Lai JL, et al (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323
10. Pedersen-Bjergaard J, Philip P, Larsen SO, et al (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1891
11. Giagounidis AAN, Germing U, Aul C (2006) Biologic and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12:5-10.
12. Jaju RJ, Boultwood J, Oliver FJ, et al (1998) Molecular cytogenetic delineation of the critical deleted region in the del(5q) syndrome. Genes Chromosomes Cancer 22:251-256
13. Nagarajan L (1995) Molecular analysis of the del(5q) chromosome. Leuk Lymphoma 17:361-366
14. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 1997, 278: 1059-1106.
15. Marriott JB, Muller G, Stirling D, Dalgleish AG (2001) Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 1(4):675-682
16. List A, Kurtin S, Roe DJ, et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557.
17. List A, Dewald G, Bennett J, et al. (2006) Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456-1465
18. Ebert BL, Galili N, Tamayo P, et al.: An erythroid differentiation gene expression signature predicts response to Lenalidomide in myelodysplasia. Am Soc Hematol, Abstract #2668 Blood 2006, 108(11).
19. Liang H, Fairman J, Claxton DF, et al.: Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: Evidence for multiple critical loci. Proc Natl Acad Sci USA 1998, 95: 3781-3785.
20. Smith SM, Le Beau MM, Huo D, et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52
21. Luna-Fineman S, Shannon KM, Atwater SK, et al (1999) Myelodysplastic and myeloproliferative disorders of childhood: A Study of 167 Patients. Blood 93:459-466
22. Kardos G, Baumann I, Passmore SJ, et al (2003) Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 102:1997-2003
23. Aktas D, Tuncbilek E (2006) Myelodysplastic syndrome associated with monosomy 7 in childhood: A retrospective study. Cancer Genet Cytogenet 171(1):72-75
24. van Lom K, Hagemeijer A, Smit E, et al (1995) Cytogenetic clonality analysis in myelodysplastic syndromes: Monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia 9(11):1818-1821
25. Sevilla J, Querol S, Molines A, et al (2006) Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. Eur J Haematol 77(3):259-263
26. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK (2006) Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20:1943-1949
27. Sloand EM, Mainwaring L, Fuhrer M, et al (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106(3):841-851
28. Sole F, Espinet B, Sanz G, Cervera J, et al (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 108:346-356
29. Sloand EM, Pfannes L, Chen G, et al.: CD34 cells from trisomy 8 MDS patients express early apoptotic markers but avoid programmed cell death by upregulation of anti-apoptotic proteins. Blood 2006, Nov 7; [Epub ahead of print].
30. Březinová J, Zemanova Z, Ransdorfová S, et al (2005) Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160(2):188-192
31. Wattel E, Lai JL, Hebbar M, Preudhomme C, et al (1993) De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: A subtype of MDS with distinct hematological and prognostic features. Leuk Res 17(11):921-926
32. Liu YC, Ito Y, Hsiao HH, et al (2006) Risk factor analysis in myelodysplastic syndrome patients with del(20q): Prognosis revisited. Cancer Genet Cytogenet 171(1):9-16
33. Chen B, Zhao WL, Jin J, et al (2005) Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 19:767-775
34. Matsushima T, Handa H, Yokohama A, et al.: Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003, 101(9): 3386-3390. [Epub 2002]
35. Cools J, DeAngelo DJ, Gotlib J, et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201-1214. This is the first report of the molecular target of imatinib in HES.
36. SchalleR JL, Burkland GA: Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001, 3: 9
37. Gleich GJ, Leiferman KM, Pardanani A, et al (2002) Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 359:1577-1578
38. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881-884
39. Cortes J, Ault P, Koller C, et al (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714-4716
40. Gotlib J (2005) Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 Update. Acta Haematol. 114(1):7-25
41. Jovanovic J, Score J, Waghorn K, et al.: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007 Feb 13; [Epub ahead of print]
42. Berkowicz M, Rosner E, Rechavi G, et al (1991) Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. Cancer Genet Cytogenet 51(2):277-278
43. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316
44. Carroll M, Tomasson MH, Barker GF, et al.: The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996, 93(25): 14845-14850.
45. Yoon SY, Tefferi A, Li CY (2000) Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Hematol 104:151-157
46. Ross TS, Bernard OA, Berger R, Gilliland DG (1998) Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91:4419-4426
47. Kulkarni S, Heath C, Parker S, et al (2000) Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 60:3529-3598
48. Magnusson MK, Meade KE, Brown KE, et al (2001) Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98:2518-2525
49. Abe A, Emi N, Tanimoto M, et al (1997) Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90:4271-4277
50. Wlodarska I, Mecucci C, Marynen P, et al (1995) TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood. 85(10):2848-2852
51. Odero MD, Vizmanos JL, Roman JP, et al (2002) A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer 35(1):11-19
52. Apperley JF, Gardembas M, Melo JV, et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487
53. Cortes J, Giles F, O'Brien S, et al.: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003, 97: 2760-2766.
54. Raza A, Lisak L, Dutt D, et al (2001) Gleevec (imatinib mesylate) in 16 patients with Chronic Myelomonocytic leukemia (CMMoL) (abstract). Blood 98:273b.